Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 16:9:699450.
doi: 10.3389/fbioe.2021.699450. eCollection 2021.

Current Strategies for Microbubble-Based Thrombus Targeting: Activation-Specific Epitopes and Small Molecular Ligands

Zhaojian Wang  1 , Huaigu Huang  1 , Yuexin Chen  1 , Yuehong Zheng  1
Affiliations
Review

Current Strategies for Microbubble-Based Thrombus Targeting: Activation-Specific Epitopes and Small Molecular Ligands

Zhaojian Wang et al. Front Bioeng Biotechnol. .

Abstract

Microbubbles with enhanced ultrasound represent a potentially potent evolution to the administration of a free drug in the treatment of thrombotic diseases. Conformational and expressional changes of several thrombotic biological components during active coagulation provide epitopes that allow site-specific delivery of microbubble-based agents to the thrombus for theranostic purpose. Through the interaction with these epitopes, emerging high-affinity small molecular ligands are able to selectively target the thrombi with tremendous advantages over traditional antibody-based strategy. In this mini-review, we summarize recent novel strategies for microbubble-based targeting of thrombus through epitopes located at activated platelets and fibrin. We also discuss the challenges of current targeting modalities and supramolecular carrier systems for their translational use in thrombotic pathologies.

Keywords: activation-specific probe; microbubbles; small molecular ligand; supramolecular carriers; thrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer YZ declared a shared affiliation, with no collaboration, with the authors ZW, HH, YC, and YZ to the handling editor at the time of the review.

Figures

FIGURE 1
FIGURE 1
Schematic representations of (A) arterial and venous thrombus, candidate-targeting epitopes, and (B) microbubble-based thrombus-targeting strategies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Absar S., Nahar K., Kwon Y. M., Ahsan F. (2013). Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy. Pharm. Res. 30 1663–1676. 10.1007/s11095-013-1011-x - DOI - PubMed
    1. Agemy L., Sugahara K. N., Kotamraju V. R., Gujraty K., Girard O. M., Kono Y., et al. (2010). Nanoparticle-induced vascular blockade in human prostate cancer. Blood 116 2847–2856. 10.1182/blood-2010-03-274258 - DOI - PMC - PubMed
    1. Ahrens I., Peter K. (2008). Therapeutic integrin inhibition: allosteric and activation-specific inhibition strategies may surpass the initial ligand-mimetic strategies. Thromb. Haemost. 99 803–804. 10.1160/th08-03-0194 - DOI - PubMed
    1. Alonso A., Della Martina A., Stroick M., Fatar M., Griebe M., Pochon S., et al. (2007). Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound. Stroke 38 1508–1514. 10.1161/strokeaha.106.471391 - DOI - PubMed
    1. André P. (2004). P-selectin in haemostasis. Br. J. Haematol. 126 298–306. 10.1111/j.1365-2141.2004.05032.x - DOI - PubMed

LinkOut - more resources